2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.110 Umit Tapan NACLC23 Abstract

PP01.110 Umit Tapan NACLC23 Abstract

Pdf Summary

This study aimed to evaluate the relationship between social determinants of health (SDOH) and treatment patterns and outcomes in patients with metastatic non-small cell lung cancer (NSCLC) in a US real-world setting. The study used de-identified patient data from commercially insured claims, electronic medical records (EMR), and neighborhood-level SDOH data. A total of 869 patients were included in the study.<br /><br />The results showed that 75% of patients received systemic first-line treatment, with the most common regimen being immunotherapy plus chemotherapy. The median time to treatment was 38 days. About 44% of patients had evidence of second-line therapy, with docetaxel plus ramucirumab being the most common regimen. The median time to second-line treatment was 32 days.<br /><br />The study also examined the association between treatment and SDOH components. Controlling for neighborhood socioeconomic status, patient Eastern Cooperative Oncology Group Performance status, age category, geographic region, and gender, the study found that Black patients were less likely to receive immunotherapy than White patients. Black patients had a shorter overall survival (OS) and longer time to first-line treatment compared to White patients.<br /><br />In conclusion, this study suggests that there is a relationship between social determinants of health and treatment patterns and outcomes in patients with metastatic NSCLC. Black patients had worse outcomes and were less likely to receive immunotherapy compared to White patients. Further research is needed to understand the underlying factors contributing to these findings.

Keywords

social determinants of health

treatment patterns

outcomes

metastatic non-small cell lung cancer

US real-world setting

immunotherapy plus chemotherapy

second-line therapy

Black patients

White patients

overall survival